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Abstract
Age-related macular degeneration (AMD) is a common condition that leads to severe vision loss and dysregulation of the
complement system is thought to be associated with the disease. To investigate associations of polymorphisms in AMD
susceptibility genes with systemic complement activation, 2655 individuals were genotyped for 32 single nucleotide
polymorphisms (SNPs) in or near 23 AMD associated risk genes. Component 3 (C3) and its catabolic fragment C3d were
measured in serum and AMD staging was performed using multimodal imaging. The C3d/C3 ratio was calculated and
associations with environmental factors, SNPs and various haplotypes of complement factor H (CFH) genes and complement
factor B (CFB) genes were analyzed. Linear models were built to measure the influence of genetic variants on the C3d/C3
ratio. The study cohort included 1387 patients with AMD and 1268 controls. Higher C3d/C3 ratios were found for current
smoker (p = 0.002), higher age (p = 1.5661027), AMD phenotype (p = 1.15610211) and the two SNPs in the C3 gene
rs6795735 (p = 0.04) and rs2230199 (p = 0.04). Lower C3d/C3 ratios were found for diabetes (p = 2.8761026), higher body
mass index (p = 1.00610213), the SNPs rs1410996 (p = 0.0001), rs800292 (p = 0.003), rs12144939 (p = 4.6061026) in CFH,
rs4151667 (p = 1.0161025) in CFB and individual haplotypes in CFH and CFB. The linear model revealed a corrected R-square
of 0.063 including age, smoking status, gender, and genetic polymorphisms explaining 6.3% of the C3d/C3 ratio. After
adding the AMD status the corrected R-square was 0.067. In conclusion, none of the evaluated genetic polymorphisms
showed an association with increased systemic complement activation apart from two SNPs in the C3 gene. Major genetic
and non-genetic factors for AMD were not associated with systemic complement activation.
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Introduction
Age-related macular degeneration (AMD) is a neurodegenera-
tive disease causing visual impairment and blindness in the elderly
population. Accumulation of drusen between Bruchs membrane
and the retinal pigment epithelium characterizes the early forms
while the two advanced forms show geographic atrophy and
choroidal neovascularization. Risk is multifactorial including
environmental and genetic factors. Genetic variation accounts
for up to 71% of the disease risk [1]. Many genetic polymorphisms
were found in the alternative pathway of the complement system
including complement factor H (CFH), complement component 3 (C3),
Complement factor I (CFI), and complement factor B (C2/CFB locus) [2–
8]. Complement proteins and their activation products have been
identified in retinal deposits of AMD patients [3,9–11].
The alternative complement pathway is constantly activated by
the spontaneous hydrolysis of a thioester bond in C3 and a tight
regulation including CFH is necessary to prevent excessive
activation. It is hypothesized that a dysregulation of the
complement system leads to tissue damage and finally AMD.
The dysregulation of the complement system or their activation
fragments were also found systemically. In AMD patients, various
components of the complement system were found at increased
levels such as CFB, CFD, C3a, C5a, C3d, and Ba [12,13].
While the association of genetic polymorphisms with AMD is
well established, only polymorphisms in the C3 gene and few
haplotypes in the CFH and CFB/C2 gene were found to be
associated with complement activation products including factor
C3d in two small cohorts [12,13]. The impact of other AMD
susceptibility genes on the regulation of systemic complement
activation remains unclear. In our study, we analyzed the
association of 32 single nucleotide polymorphisms (SNPs) in or
near 23 AMD risk genes with the C3d/C3 ratio as a marker for
chronic complement activation in a Caucasian cohort of 2655
participants.
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e93459
Methods
Study population
2655 participants from the European Genetic Database
(EUGENDA, www.eugenda.org) were included in the study.
The study was performed in accordance with the tenets of the
Declaration of Helsinki and the Medical Research Involving
Human Subjects Act (WMO) and was approved by the local ethics
committee of the University Hospitals in Cologne and Nijmegen.
Written informed consent was obtained from all participants.
AMD staging was performed by grading of retinal images
including stereo fundus photographs (FPs), fluorescein angiograms
(FAs) and spectral domain optical coherence tomograms
(SDOCTs) according to the standard protocol of the Cologne
Image Reading Center (CIRCL) by certified graders (TR, LE).
AMD was classified by the presence of pigmentary changes
together with at least 10 small drusen (,63 mm) or the presence of
intermediate (63–124 mm) or large drusen ($125 mm diameter) in
the Early Treatment Diabetic Maculopathy Study (ETDRS) grid
or geographic atrophy and/or choroidal neovascularisation (CNV)
secondary to AMD in at least one eye.
Demographic data and non-genetic parameters including
history of smoking (current/past/never), regular alcohol intake
(yes/no), body mass index (BMI), arterial hypertension (yes/no),
diabetes (yes/no), rheumatoid arthritis (yes/no), thyroid disease
(yes/no), kidney disease (yes/no) and history of allergy (yes/no)
were obtained by standardized interviewer-assisted questionnaires.
Complement component measurements and genetic
analysis
Serum samples were used for C3d and C3 measurements.
Serum was prepared by coagulation at room temperature. After
centrifugation, the samples were stored at 280uC within 1 hour
after collection. Complement component C3 and the activation
fragment C3d were measured in serum samples as described
previously [14]. The C3d/C3 ratio was calculated as a measure of
C3 activation.
Genomic DNA was extracted from peripheral blood samples
using standard procedures. Thirty-two SNPs in or near 23 AMD
associated risk genes were chosen representing the majority of loci
associated with AMD. Genotyping of SNPs in the ARMS2
(rs10490924), CFH (rs1061170, rs800292, rs12144939,
rs1410996), CFI (rs10033900, rs141853578), C2 (rs9332739), C3
(rs2230199, rs433594, rs6795735), CFB (rs4151667, rs641153),
CFD (rs3826945), LPL (rs12678919), LIPC (rs10468017), TIMP3
(rs9621532), APOE2 (rs7412), APOE4 (rs429358), FADS1
(rs174547), CETP (rs2230199), TLR (rs4986790, rs3775291),
Table 1. Median C3d/C3 ratios for non-genetic factors.
Non-genetic factor N (%) Median C3d/C3 ratio (IQR) T-test/univariate ANOVA
Female sex 1547 (58.3) 0.00424 (0.00325–0.00561) 0.90
Male sex 1108 (41.7) 0.00433 (0.00328–0.00567)
Age 50–59 years 61 (2.3) 0.00430 (0.00337–0.00598) 1.5661027
Age 60–69 years 879 (33.1) 0.00408 (0.00312–0.00550)
Age 70–79 years 1140 (42.9) 0.00426 (0.00324–0.00547)
Age 80–89 years 474 (17.9) 0.00462 (0.00356–0.00591)
Age 90–99 years 97 (3.7) 0.00488 (0.00374–0.00705)
No AMD 1268 (47.8) 0.00403 (0.00309–0.00536) 1.15610211
AMD 1387 (52.2) 0.00449 (0.00348–0.00586)
No arterial hypertension 1600 (63.6) 0.00428 (0.00328–0.00563) 0.24
Arterial hypertension 917 (36.4) 0.00425 (0.00321–0.00556)
No diabetes 2268 (90.8) 0.00430 (0.00330–0.00567) 2.8761026
Diabetes 231 (9.2) 0.00390 (0.00295–0.00495)
No rheumatoid arthritis 2353 (93.5) 0.00426 (0.00327–0.00559) 0.35
Rheumatoid arthritis 164 (6.5) 0.00433 (0.00304–0.00564)
No thyroid disease 2119 (84.2) 0.00426 (0.00326–0.00559) 0.77
Thyroid disease 398 (15.8) 0.00429 (0.00325–0.00559)
No kidney disease 2403 (95.5) 0.00426 (0.00326–0.00559) 0.92
Kidney disease 114 (4.5) 0.00447 (0.00320–0.00572)
No allergy 1984 (78.8) 0.00428 (0.00325–0.00562) 0.75
Allergy 533 (21.2) 0.00425 (0.00328–0.00552)
Never smoker 1029 (43.0) 0.00431 (0.00325–0.00572) 0.002
Past smoker 1164 (48.6) 0.00415 (0.00320–0.00545)
Current smoker 201 (8.4) 0.00451 (0.00355–0.00584)
BMI ,25 930 (40.1) 0.00464 (0.00360–0.00611) 1.00610213
BMI 25–29 1084 (46.7) 0.00408 (0.00312–0.00531)
BMI $30 308 (13.3) 0.00376 (0.00287–0.00493)
IQR = interquartile range (1st quartile – 3rd quartile).
doi:10.1371/journal.pone.0093459.t001
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Figure 1. Logarithmic C3d/C3 ratios for haplotypes in the CFH gene rs1061170, rs800292 and rs12144939.
doi:10.1371/journal.pone.0093459.g001
Figure 2. Logarithmic C3d/C3 ratios for haplotypes in the CFB gene rs4151667 and rs641153.
doi:10.1371/journal.pone.0093459.g002
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SERPING (rs2511989), ABCA4 (rs1800555, rs1800553,
rs76157638), VEGFA (rs699946), SPRYD7 (rs7995557), COL8A1
(rs13081855), COL10A1 (rs3812111), SLC16A8 (rs8135665),
ADAMTS9-AS2 (rs6795735) genes were carried out as previously
described [15].
Haplotype analysis
In order to analyze the influence of haplotypes on C3d/C3
ratios, the posterior probability of each haplotype in the CFH gene
including rs1061170, rs800292 and rs12144939 and in the CFB
gene including rs4151667 and rs641153 was calculated using
PHASE software, version 2.1 [16,17].
Statistical analysis
All calculations were performed using SPSS software version
21.0 (IBM Software and Systems, Armonk, NY, USA). C3d/C3
ratios are given as median and interquartile range (1st quartile –
3rd quartile). Due to the skewed nature of the data, the logarithm
(log10) of the C3d/C3 ratios was used for analysis. Associations
between logarithmic C3d/C3 ratios and genetic polymorphisms,
haplotypes, phenotype and environmental factors were analyzed
using t-tests or univariate analysis of variance (ANOVA) depend-
ing on number of variables. Associations between AMD pheno-
type and genetic polymorphisms were evaluated using logistic
regression analysis. Linear models were performed to illustrate the
influence of the genetic factors on complement activation. P-
Values ,0.05 were considered statistically significant.
Results
Demographics and non-genetic factors
Mean age of the study population was 73.268.0 years
(75.868.1 years for AMD patients and 70.466.8 years for
controls, p,0.001). Demographic data, phenotype and environ-
mental factors are summarized in Table 1. C3d/C3 ratios showed
significant differences for age with increasing levels (except the
youngest group from 50–59 years) and phenotype with higher
values for AMD patients. A significant association was also found
for diabetes, smoking, and BMI.
Associations of C3d/C3 levels with genetic
polymorphisms
Significant associations of C3d/C3 levels were found in the CFH
gene for the SNPs rs1410996, rs800292 and rs12144939, in the
CFB gene for rs4151667 and in the C3 gene for rs6795735 and
rs2230199. In all SNPs of the CFH and CFB gene, these variants
showed lower C3d/C3 ratios than the reference alleles, only
variants in C3 revealed higher values. After stratification in AMD
cases and controls, associations for the major risk variants in
rs1061170 (CFHY402H, p = 0.35 for no AMD; p= 0.55 for AMD)
and rs10490924 (ARMS2, p = 0.75 for No AMD, p=0.25 for
AMD) with the C3d/C3 ratio could not be observed. A detailed
analysis is outlined in Table 2.
For the SNPs rs1061170, rs800292 and rs12144939 in the CFH
gene and the SNPs rs4151667 and rs641153 in the CFB gene,
haplotypes were associated with C3d/C3 levels (Table 3). All
haplotypes were associated with lower C3d/C3 levels than the
reference haplotype (Figure 1 and 2).
Associations of genetic polymorphisms with AMD
Performing logistic regression analysis, protective effects were
found for variants in CFH rs1410996, CFH rs800292, CFH
rs12144939, CFB rs641153 and FADS1 rs174547. Variants in CFB
rs4151667, TIMP3 rs9621532 and APOE4 rs429358 showed a trend
for a protective effect on AMD without reaching statistical
significance, which may be due to low minor allele frequencies
or smaller effects of those SNPs.
Variants in ARMS2 rs10490924, CFH rs1061170, C3
rs2230199, C3 rs6795735 and CETP rs2230199 were found to
be associated with significantly higher risk for AMD (Table 4).
Variants in VEGFA rs699946, SLC16A8 rs8135665 and ADAMTS9-
AS2 rs6795735 also showed a trend for a higher AMD risk without
statistical significance, which also may be due to a smaller effect on
AMD development for each of those SNPs compared to ARMS2
rs10490924 or CFH rs1061170.
Linear Models
Linear models were composed based on univariate analysis of
covariance (ANCOVA) with the logarithmic C3d/C3 ratio as
dependent variable to evaluate the influence of various factors on
the C3d/C3 ratio. In the first model, we included all SNPs
(rs1410996, rs800292, rs12144939 in CFH, rs4151667 in CFB,
Table 3. Haplotypes for CFH/CFB and median C3d/C3 ratios.
Haplotype CFH n Haplotype frequency MedianC3d/C3 ratio (IQR) T-test
TGG 728 0.20 0.00456 (0.00345–0.00608) -*
CGG 1544 0.42 0.00420 (0.00324–0.00550) 1.4061028
TAG 755 0.20 0.00405 (0.00314–0.00530) 3.61610212
TGT 620 0.17 0.00386 (0.00300–0.00504) 1.03610213
CAG 21 0.008 0.00396 (0.00339–0.00507) -**
TAT 18 0.005 0.00386 (0.00317–0.00513) -**
Haplotype CFB n Haplotype frequency MedianC3d/C3 ratio (IQR) T-test
TG 3337 0.89 0.00424 (0.00325–0.00559) -*
TA 279 0.07 0.00408 (0.00310–0.00546) 0.15
AG 152 0.04 0.00356 (0.00292–0.00471) 9.9661026
For CFH single nucleotides polymorphisms rs1061170, rs800292, and rs12144939 and for CFB rs4151667 and rs641153 were chosen.
*T- test with comparison to reference haplotypes TGG and TG; **Due to small number of cases excluded from analysis; IQR = interquartile range (1st quartile – 3rd
quartile).
doi:10.1371/journal.pone.0093459.t003
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rs6795735 and rs2230199 in C3) that had reached statistical
signifcance in the individual analysis and the two major AMD risk
SNPs risk ARMS2 rs10490924 and CFH rs1061170. Additionally,
age, gender, and smoking status was included. The corrected R-
square was 0.063. Adding the AMD status to the model, the
corrected R-square was 0.067.
In the second model, CFH haplotypes, age, gender, and
smoking status were included. The corrected R-square was 0.038.
Discussion
Dysregulation of the alternative complement pathway is thought
to play a key role in AMD pathogenesis, which is also reflected by
increased systemic complement levels.
In this study we analyzed the association of genetic AMD risk
polymorphisms with systemic complement activation. We identi-
fied only a few variants in the CFH, CFB, and C3 gene that showed
an association with systemic complement activation, while for all
other genetic polymorphisms associations were not observed.
While the association with genetic polymorphisms was weak, we
found a significant association of the phenotype AMD with an
increased C3d/C3 ratio which is in line with other smaller
studies.[12,13] Our linear model including the AMD phenotype,
the two major non-genetic risk factors age and smoking, and eight
relevant SNPs could only explain 6.7% of the variation in the
C3d/C3 ratio, indicating that these AMD risk polymorphisms do
not explain sufficiently increased systemic complement activation
found in AMD patients. The inclusion of CFH haplotypes in the
Table 4. Logistic regression analysis between AMD and single nucleotide polymorphisms SNPs+.
SNP Heterozygous variant Homozygous variant
OR 95% CI P-value OR 95% CI P-value
ARMS2 rs10490924 2.32 1.90–2.84 1.00610213 8.13 5.66–11.69 1.00610213
CFH rs1061170 1.57 1.27–1.95 3.1661025 3.70 2.82–4.85 1.00610213
CFH rs1410996 0.36 0.27–0.48 5.05610212 0.23 0.15–0.36 1.28610213
CFH rs800292 0.61 0.49–0.75 5.3861026 0.70 0.44–1.10 0.12
CFH rs12144939 0.57 0.47–0.71 6.7161027 0.51 0.28–0.91 0.02
CFI rs10033900 1.07 0.85–1.35 0.59 0.99 0.76–1.28 0.93
CFI rs141853578 1.17 0.96–1.43 0.12 -* -* -*
C2 rs9332739 0.70 0.42–1.17 0.17 -* -* -*
C3 rs2230199 1.17 0.96–1.42 0.11 2.17 1.42–3.31 0.0004
C3 rs433594 0.98 0.80–1.21 0.88 0.91 0.67–1.23 0.52
C3 rs6795735 1.10 0.89–1.36 0.37 2.06 1.27–3.33 0.03
CFB rs4151667 0.74 0.52–1.05 0.08 -* -* -*
CFB rs641153 0.72 0.54–0.96 0.02 -* -* -*
CFD rs3826945 1.01 0.76–1.34 0.94 0.76 0.48–1.22 0.26
LPL rs12678919 1.02 0.80–1.29 0.89 1.11 0.51–2.43 0.79
LIPC rs10468017 0.94 0.78–1.14 0.53 0.63 0.43–0.93 0.19
TIMP3 rs9621532 0.86 0.52–1.42 0.56 -* -* -*
APOE2 rs7412 1.21 0.84–1.76 0.31 -* -* -*
APOE4 rs429358 0.84 0.60–1.17 0.30 -* -* -*
FADS1 rs174547 0.88 0.72–1.06 0.18 0.64 0.46–0.88 0.006
CETP rs2230199 1.39 1.15–1.70 0.001 1.38 1.02–1.87 0.04
TLR rs4986790 1.08 0.71–1.64 0.71 0.53 0.08–3.36 0.50
TLR3 rs3775291 1.00 0.75–1.34 0.99 0.78 0.48–1.27 0.32
SERPING rs2511989 1.10 0.81–1.50 0.53 0.79 0.54–1.16 0.22
ABCA4D2177 rs1800555 0.96 0.33–2.82 0.94 -* -* -*
ABCA4G1961 rs1800553 0.88 0.12–6.58 0.90 -* -* -*
ABCA4 rs76157638 2.14 0.98–4.67 0.06 -* -* -*
VEGFA rs699946 1.08 0.81–1.44 0.61 1.47 0.75.2.89 0.27
SPRYD7 rs7995557 1.01 0.73–1.40 0.95 0.57 0.23–1.43 0.23
COL8A1 rs13081855 1.03 0.80–1.33 0.82 0.53 0.16–1.74 0.30
COL10A1 rs3812111 1.04 0.84–1.28 0.73 1.02 0.75–1.40 0.89
SLC16A8 rs8135665 1.21 0.98–1.49 0.08 1.39 0.87–2.21 0.17
ADAMTS9-AS2 rs6795735 1.21 0.98–1.51 0.08 1.30 0.98–1.72 0.07
+Adjusted for age and gender; *analysis not performed due to small group size.
doi:10.1371/journal.pone.0093459.t004
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model revealed an even lower explanation of the C3d/C3 ratio of
only 3.8%.
Our analysis concentrated on C3d as a marker of chronic
complement activation because it is a relatively stable protein with
a long half-life. To correct for differences in the concentration of
the precursor protein, we also measured C3 in the plasma.
CFH, CFB, and C3 influence the regulation of the alternative
pathway of the complement system. CFH acts as the major
regulator of complement activation controlling the alternative
pathway in blood and on cell surfaces [18], and accelerates the
decay of the alternative C3 convertase (C3bBb) [19].
CFH is also a cofactor of CFI-mediated cleavage and
inactivation of C3b [20]. The formation of C3d, a polypeptide
fragment generated during alternative C3 convertase cleaves C3 to
C3b, is also CFH dependent [21]. Alterations in the CFH gene
may change the regulating characteristics of CFH resulting in an
up or down regulation of the CFH dependent elements of the
alternative complement pathway. In our cohort, SNPs rs1410996,
rs800292, and rs12144939 in the CFH gene were associated with
lower C3d/C3 ratios and a lower risk for AMD, whereas the most
common AMD risk variant rs1061170 was not associated with the
C3d/C3 ratio even after stratification in AMD patients and
controls. Additionally, CFH haplotypes showed lower C3d/C3
ratios in all cases compared to the reference haplotype. Therefore,
CFH SNPs were not associated with increased systemic comple-
ment activation.
CFB is an acute phase protein involved in the alternative
complement pathway as a precursor of C3 convertase. CFB is
cleaved to Bb which combines with C3b to form the alternative
pathway C3 convertase C3bBb. An acute phase response-
mediated up-regulation may result in elevated systemic plasma
levels of CFB in AMD patients and may contribute to an
enhanced systemic complement activity [12,13,22]. In our study
we observed lower C3d/C3 ratios for the operatively protective
CFB variants for AMD indicating that individuals with these
polymorphisms show less complement activation.
Among all analyzed SNPs, only variants in the C3 gene were
associated with higher systemic C3d/C3 ratios which aligns with
the results by Hecker et al.11 The alternative pathway of the
complement system starts with spontaneous hydrolysis of C3 and
variants with a higher risk for AMD seem to influence this part of
the complement cascade resulting in elevated systemic comple-
ment activation. Scholl et al did not observe a correlation between
genetic variants in C3 and systemic C3d levels12 underlining that
the systemic effects of AMD susceptibility genes on complement
activation are only weak.
In our study, slightly higher C3d/C3 levels were found in AMD
patients. In order to not miss a combined effect of multiple SNPs,
we performed linear models to illustrate the effect of the
combination of SNPs on complement activation. These models
could not explain the C3d/C3 ratio, showing that there have to be
other systemic effects than AMD phenotype or genetic variants
influencing systemic complement activation. Hecker et al also
showed in a small cohort that risk haplotypes in CFH did not alter
complement levels, whereas protective haplotypes reduced com-
plement levels including C3d [12].
A limitation of our study is the analysis of only two components
of the complement system, which is accompanied by several
strengths including a large cohort of well-balanced AMD patients
and controls, a high number of investigated SNPs and the use of
multimodal imaging that avoids misclassification of phenotypes.
In summary, we showed that the major AMD risk polymor-
phisms in CFH and ARMS2 are not associated with increased
systemic complement activation as measured by the C3d/C3 ratio.
Few SNPs were associated with lower levels of systemic
complement activation, particularly the CFH and CFB polymor-
phisms that are protective against AMD. Only variants in C3 were
associated with elevated complement levels. Furthermore, a model
including major genetic and non-genetic factors for AMD was not
able to explain complement activation.
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